What is a stock summary page? Click here for an overview.
Business Description
Collegium Pharmaceutical Inc
NAICS : 325412
SIC : 2834
ISIN : US19459J1043
Compare
Compare
Traded in other countries / regions
COLL.USA354.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2015-05-07Description
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.19 | |||||
| Equity-to-Asset | 0.14 | |||||
| Debt-to-Equity | 3.76 | |||||
| Debt-to-EBITDA | 2.52 | |||||
| Interest Coverage | 2.26 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 0.96 | |||||
| Beneish M-Score | -2.49 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 32.3 | |||||
| 3-Year EBITDA Growth Rate | 58.8 | |||||
| 3-Year EPS without NRI Growth Rate | 35.7 | |||||
| 3-Year FCF Growth Rate | 26.7 | |||||
| 3-Year Book Growth Rate | 6.5 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 4.42 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.78 | |||||
| 9-Day RSI | 52.89 | |||||
| 14-Day RSI | 51.11 | |||||
| 3-1 Month Momentum % | -3.87 | |||||
| 6-1 Month Momentum % | -26.31 | |||||
| 12-1 Month Momentum % | -29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.95 | |||||
| Quick Ratio | 0.88 | |||||
| Cash Ratio | 0.32 | |||||
| Days Inventory | 47.42 | |||||
| Days Sales Outstanding | 115.04 | |||||
| Days Payable | 6.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 2.2 | |||||
| Shareholder Yield % | 7.38 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 59.76 | |||||
| Operating Margin % | 26.44 | |||||
| Net Margin % | 10.96 | |||||
| FCF Margin % | 32.2 | |||||
| ROE % | 31.53 | |||||
| ROA % | 5.23 | |||||
| ROIC % | 12.18 | |||||
| 3-Year ROIIC % | 70.98 | |||||
| ROC (Joel Greenblatt) % | 823.32 | |||||
| ROCE % | 20.18 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 16.1 | |||||
| Forward PE Ratio | 4.33 | |||||
| PE Ratio without NRI | 4.64 | |||||
| Price-to-Owner-Earnings | 15.01 | |||||
| PS Ratio | 1.93 | |||||
| PB Ratio | 4.11 | |||||
| Price-to-Free-Cash-Flow | 6 | |||||
| Price-to-Operating-Cash-Flow | 5.95 | |||||
| EV-to-EBIT | 9.54 | |||||
| EV-to-EBITDA | 4.82 | |||||
| EV-to-Revenue | 2.61 | |||||
| EV-to-Forward-Revenue | 2.22 | |||||
| EV-to-FCF | 8.09 | |||||
| Price-to-GF-Value | 0.83 | |||||
| Price-to-Projected-FCF | 1.07 | |||||
| Earnings Yield (Greenblatt) % | 10.48 | |||||
| FCF Yield % | 21.57 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:COLL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Collegium Pharmaceutical Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 631.449 | ||
| EPS (TTM) ($) | 1.86 | ||
| Beta | 0.87 | ||
| 3-Year Sharpe Ratio | 0.43 | ||
| 3-Year Sortino Ratio | 0.76 | ||
| Volatility % | 33.98 | ||
| 14-Day RSI | 51.11 | ||
| 14-Day ATR ($) | 1.046183 | ||
| 20-Day SMA ($) | 29.448 | ||
| 12-1 Month Momentum % | -29 | ||
| 52-Week Range ($) | 27.275 - 42.2873 | ||
| Shares Outstanding (Mil) | 31.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Collegium Pharmaceutical Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Collegium Pharmaceutical Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Collegium Pharmaceutical Inc Frequently Asked Questions
What is Collegium Pharmaceutical Inc(COLL)'s stock price today?
The current price of COLL is $29.96. The 52 week high of COLL is $42.29 and 52 week low is $27.28.
When is next earnings date of Collegium Pharmaceutical Inc(COLL)?
The next earnings date of Collegium Pharmaceutical Inc(COLL) is 2025-05-09 Est..
Does Collegium Pharmaceutical Inc(COLL) pay dividends? If so, how much?
Collegium Pharmaceutical Inc(COLL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers